Related Experiment Video
Updated: Apr 25, 2026
07:46
Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus MRSA in Rat
Published on: June 4, 2012
16.7K
High-dose daptomycin therapy for staphylococcal endocarditis and when to apply it.
Jordan R Smith1, Kimberly C Claeys, Katie E Barber
1Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, 48201, USA, cm7481@wayne.edu.
Current Infectious Disease Reports
|August 29, 2014
Summary
High-dose daptomycin may offer improved treatment for difficult Staphylococcus aureus infective endocarditis cases. This approach shows promise for patients with vancomycin treatment failure or resistance.
Area of Science:
- Infectious Diseases
- Pharmacology
- Cardiology
Background:
- Infective endocarditis (IE) poses a significant health burden, with Staphylococcus aureus as the primary pathogen.
- Increasing vancomycin resistance in S. aureus limits treatment options for IE.
- Daptomycin is a key alternative when vancomycin is ineffective or MICs are elevated.
Purpose of the Study:
- To evaluate the potential role of high-dose daptomycin (up to 12 mg/kg/day) in treating Staphylococcus aureus infective endocarditis.
- To assess the efficacy and safety of higher daptomycin dosages compared to standard therapy.
Main Methods:
- Review of in vitro and clinical studies investigating daptomycin efficacy in S. aureus infections.
- Analysis of data on daptomycin dosing, vancomycin minimum inhibitory concentrations (MICs), and patient outcomes.
Main Results:
- Studies suggest higher daptomycin doses (up to 12 mg/kg/day) may enhance efficacy and prevent resistance.
- High-dose daptomycin has demonstrated a favorable safety profile.
- Elevated vancomycin MICs and prior treatment failures are key indicators for considering alternative therapies.
Conclusions:
- High-dose daptomycin (up to 12 mg/kg/day) shows potential as an effective treatment for severe Staphylococcus aureus IE.
- This strategy is particularly relevant for critically ill patients, those with vancomycin treatment failure, or isolates with elevated vancomycin MICs.
Related Concept Videos
01:18Endocarditis III: Medical Management
359
Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
359
01:29Endocarditis IV: Nursing Management
627
Infective endocarditis (IE) is a chronic infection of the heart's endocardium, primarily affecting the heart valves. A detailed nursing assessment for a patient with IE involves collecting subjective and objective data to ensure an accurate diagnosis and timely intervention.Subjective DataThe nurse gathers information about the patient's symptoms and complaints during the subjective assessment. Patients with infective endocarditis often report non-specific symptoms that can mimic other...
627
01:25Endocarditis I: Introduction
862
Introduction:Endocarditis is the infection of the endocardium, the inner lining of the heart and its valves. When the heart muscle is involved, the condition is termed myocarditis, while an infection of the outer lining is called pericarditis. Infective endocarditis (IE) primarily affects the endocardium, where pathogens adhere to the valves or lining, forming vegetation that can lead to severe complications. Infective endocarditis occurs when microorganisms, usually bacteria from other body...
862
01:30Cardiomyopathy II: Dilated Cardiomyopathy
785
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
785
01:14Myocarditis III: Medical Management
342
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
342
01:25Endocarditis II: Clinical Features of Infective Endocarditis
918
Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
918